Search


SF Healthcare Week: Insmed CEO Will Lewis discusses the launch BRINSUPRI and pipeline readouts ahead in 2026
He discusses the $145M 4Q number that was announced at JPM, and the real world feedback the company has been receiving from physicians and patients. Plus, how the thinks about Insmed now that it is a $35B market cap company.
Jan 14


Insmed's CEO on the success of brensocatib in bronchiectasis and what it means for the company
Will Lewis describes last week's data and what means not just for bronchiectasis but also as a broader proof of concept for DPP1...
Jun 6, 2024






.png)
